Company intelligence / Profile preview

Recross Cardio

Dover, Delaware, United Statesrecrosscardio.com ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

The company's main product, the Recross Septal Occluder, uses a patented polymer skin to preserve future access to the left heart. It targets congenital and structural cardiac conditions requiring transcatheter septal occlusion. Clinical results or trial data are not publicly available as of now.

Therapeutic areas: Cardiovascular
Modalities: DevicePolymer-based medical device
Industry: Implantable Medical Devices

Partnerships

None disclosed/publicly known as of June 2025

Beyond the preview

Go deeper on Recross Cardio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recross Cardio.

Explore the full profile